| 000 | 01600 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513034854.0 | ||
| 264 | 0 | _c19950915 | |
| 008 | 199509s 0 0 eng d | ||
| 022 | _a0269-9370 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJablonowski, H | |
| 245 | 0 | 0 |
_aA dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group. _h[electronic resource] |
| 260 |
_bAIDS (London, England) _cMay 1995 |
||
| 300 |
_a463-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aAIDS-Related Complex _xdrug therapy |
| 650 | 0 | 4 |
_aAcquired Immunodeficiency Syndrome _xdrug therapy |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 |
_aDidanosine _xadministration & dosage |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aDrug Tolerance |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPancreatitis _xchemically induced |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aZidovudine _xadverse effects |
| 700 | 1 | _aArasteh, K | |
| 700 | 1 | _aStaszewski, S | |
| 700 | 1 | _aRuf, B | |
| 700 | 1 | _aStellbrink, H J | |
| 700 | 1 | _aSchrappe, M | |
| 700 | 1 | _aStoehr, A | |
| 700 | 1 | _aHaase, W | |
| 700 | 1 | _aSchomaker, U | |
| 700 | 1 | _avon Eisenhart Rothe, B | |
| 773 | 0 |
_tAIDS (London, England) _gvol. 9 _gno. 5 _gp. 463-9 |
|
| 999 |
_c7639402 _d7639402 |
||